enGene Holdings Inc. Reports First Quarter 2026 Financial Results and Provides Major Business Update

Key Highlights

• LEGEND pivotal cohort update planned for a spring 2026 medical conference
• 12-month complete response data from LEGEND pivotal cohort expected in 2H 2026
• Biologics License Application (BLA) submission for detalimogene planned for 2H 2026
• Cash and marketable securities of \$312.5 million, providing runway into 2H 2028
• Expanded \$125 million debt facility with Hercules Capital for additional financial flexibility
• Preliminary LEGEND cohort data shows promising efficacy and safety profile
• Detalimogene awarded RMAT and Fast Track designation and selected for FDA’s CMC Development and Readiness Pilot (CDRP) program

Detailed Financial and Business Review

Strong Financial Position and Strategic Fundraising

enGene entered 2026 with a robust financial position, reporting cash, cash equivalents, and marketable securities of \$312.5 million as of January 31, 2026. This strong balance sheet is expected to fund the company’s operating expenses, debt obligations, and capital expenditures into the second half of 2028. The company has further bolstered its financial flexibility by expanding its debt facility with Hercules Capital to \$125 million. Access to this non-dilutive capital is well-timed as enGene prepares for a potential BLA submission and commercial launch of detalimogene voraplasmid, its lead gene therapy candidate for high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Additionally, enGene successfully completed a follow-on public offering in November 2025, raising \$140.1 million in net proceeds at \$8.50 per share (and \$8.4999 per pre-funded warrant). This capital raise, following the exercise of the underwriters’ option, further supports the company’s clinical and commercial ambitions.

Clinical and Regulatory Progress of Detalimogene Voraplasmid

Detalimogene voraplasmid, a novel non-viral gene therapy for high-risk NMIBC, continues to display a strong clinical profile. Preliminary data from the LEGEND pivotal cohort, shared in November 2025, demonstrated the following for patients enrolled post-protocol amendment:

• 63% complete response (CR) rate at any time (n=62)
• 56% CR rate at 3 months (n=62)
• 62% CR rate at 6 months (n=37), including patients converting to CR post-reinduction
• All 5 patients who reached the 9-month assessment remained in complete response

The safety profile was also favorable:

• 42% of patients experienced a treatment-related adverse event (TRAE)
• Only 1.6% experienced dose interruptions due to TRAEs
• Only 0.8% had dose discontinuations due to TRAEs

Enrollment for the pivotal cohort is complete at 125 patients. These results support detalimogene’s potential as a first-line therapy for high-risk, BCG-unresponsive NMIBC with carcinoma in situ (CIS).

The company will provide a pivotal cohort update at a major spring 2026 medical conference, with 12-month complete response data expected in the second half of 2026. A BLA submission for detalimogene is planned for the same period, targeting a potential commercial launch in 2027, pending FDA approval.

Regulatory Designations and FDA Collaboration

Detalimogene has received several significant regulatory accelerators, including:

• Regenerative Medicine Advanced Therapy (RMAT) designation
• Fast Track designation
• Selection for the FDA’s Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program

These designations are intended to expedite the development and review process for therapies addressing serious conditions with high unmet medical needs, positioning detalimogene as a potential rapid-to-market therapy for BCG-unresponsive NMIBC.

Financial Performance and Operating Expenses

For the quarter ended January 31, 2026:

• Total operating expenses: \$31.2 million (up from \$26.6 million in Q1 2025)
• Research and development expenses: \$22.3 million (increase driven by LEGEND trial and BLA preparation)
• General and administrative expenses: \$8.9 million (increase due to scaling for public company operations)

Net loss attributable to common shareholders was approximately \$29.8 million, or \$0.44 per share, compared to \$24.6 million, or \$0.48 per share, for the same period last year. The increase in net loss is mainly due to higher operating expenses, partially offset by net interest income.

Product and Market Overview

NMIBC represents a significant unmet need, with up to 80% of new bladder cancer diagnoses falling into this category. For patients with high-risk NMIBC unresponsive to BCG, options are limited, often requiring life-altering cystectomy. Detalimogene aims to fill this gap with a non-viral gene therapy administered directly into the bladder, designed to provoke a localized, robust anti-tumor immune response.

The Dually Derivatized Oligochitosan® (DDX) platform underlying detalimogene offers several advantages:

• Potentially overcomes limitations of viral-based gene therapies
• Reduces complexities around handling and storage
• Simplifies manufacturing and administration

Shareholder-Relevant, Price-Sensitive Updates

• Upcoming pivotal data releases at a major spring medical conference and in 2H 2026 could significantly impact the company’s valuation and share price.
• Planned BLA submission in 2H 2026 and potential commercial launch in 2027 represent critical regulatory and commercial milestones.
• Strong financial position and access to non-dilutive capital reduce near-term funding risk and support ongoing clinical and commercial activities.
• Detalimogene’s regulatory designations (RMAT, Fast Track, CDRP) increase the likelihood of expedited review and potential early approval, which is highly relevant for investors.
• Positive preliminary efficacy and safety data for detalimogene could drive investor sentiment and share price appreciation, particularly as additional data matures.

Conclusion

enGene’s first quarter 2026 results and business update highlight significant clinical, regulatory, and financial progress. The company’s lead asset, detalimogene, continues to show promise as a potential first-in-class gene therapy for a high-need bladder cancer population, with multiple upcoming milestones that could materially affect the company’s share price. Investors should closely monitor upcoming data releases and regulatory filings, as these are likely to be key drivers of shareholder value in the coming quarters.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with a financial advisor before making investment decisions. Forward-looking statements are subject to risks and uncertainties as detailed in enGene Holdings Inc.’s public filings. Actual results may differ materially from those anticipated or projected.

View enGene Holdings Inc. Historical chart here